此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Blood Tests for Alzheimer's Disease: Can Plasma Biomarkers Diagnose and Predict Disease Progression (BLAD)

2026年7月16日 更新者:Prof. Massimo Filippi、IRCCS San Raffaele

The Diagnostic and Prognostic Role of Plasma Biomarkers in Alzheimer's Disease

BLAD is a prospective, monocentric, observational epidemiological study with an additional procedure (annual blood draw) evaluating the diagnostic and prognostic performance of plasma biomarkers for Alzheimer's disease (AD) in a large cohort of patients attending the Cognitive Disorders and Dementia Center (CDCD) at IRCCS San Raffaele Hospital, Milan, Italy.

2000 patients will be enrolled and followed annually for 5 years. A validation sub-study (150 patients) will compare plasma biomarkers against CSF biomarkers as the gold standard.

The study aims to establish plasma biomarkers as a less invasive and more cost-effective alternative to CSF analysis and amyloid-PET for the diagnosis and prognosis of AD.

研究概览

地位

招聘中

条件

干预/治疗

详细说明

In light of the possible advent of disease-modifying drugs for Alzheimer's disease (AD), reliable biomarkers have been developed in recent years to define the presence of AD pathology at the brain level. The current biological gold standards are cerebrospinal fluid (CSF) biomarkers (CSF-Abeta40, CSF-Abeta42, CSF-pTau, CSF-NfL) and amyloid-PET. Both methods have excellent diagnostic properties but are costly and invasive, limiting their use outside of highly specialized centers.

Plasma biomarkers (plasma-Abeta40, plasma-Abeta42, plasma-pTau-181, plasma-NfL, plasma-ApoE, plasma-ApoE4, plasma-GFAP, plasma-sTREM2, and other plasma neurodegeneration biomarkers) represent a potentially less invasive and more economically accessible alternative. Recent studies have shown that plasma biomarkers can differentiate AD from other neurodegenerative disorders with accuracy comparable to CSF and PET, detect AD pathology in MCI patients, and predict future development of AD dementia in patients with SCD or MCI. However, more research is needed before their widespread use in clinical practice.

The BLAD study is designed as a monocentric, prospective, observational epidemiological study with an additional procedure (annual blood draw for 5 years) and a diagnostic accuracy sub-study (not device-based).

Patients will be recruited among those attending the Cognitive Disorders and Dementia Center (CDCD) at IRCCS San Raffaele Hospital during routine clinical practice. All enrolled patients will undergo annual blood sampling for 5 years in addition to standard clinical assessments.

A sub-population of 150 patients who undergo lumbar puncture as part of their routine diagnostic workup will enter the validation sub-study. Only those whose CSF biomarkers confirm a biological diagnosis of Alzheimer's disease will continue follow-up; others will exit the sub-study.

The equipment for plasma biomarker measurement (CE-marked medical device) and laboratory kits will be provided on free loan by Fujirebio. No clinical or laboratory data will be shared with Fujirebio.

Statistical analyses will include: log-rank test to compare time to AD development between groups above and below the biomarker threshold; linear stepwise regression models, linear mixed-effects models, and multivariable Cox models to assess the prognostic value of plasma biomarkers; longitudinal generalized linear models for repeated measures or Wilcoxon test to assess biomarker dynamics over time. For the validation sub-study, ROC curve analysis will be performed to assess accuracy, sensitivity, and specificity of plasma biomarkers against CSF gold standard.

研究类型

观察性的

注册 (估计的)

2000

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:Giuseppe Magnani, MD

学习地点

    • Milano
      • Milan、Milano、意大利、20132
        • 招聘中
        • IRCCS Ospedale San Raffaele - Cognitive Disorders and Dementia Center (CDCD)
        • 接触:
        • 接触:
          • Giuseppe Magnani, MD
        • 首席研究员:
          • Massimo Filippi, Prof, MD
        • 副研究员:
          • Federica Agosta, MD
        • 副研究员:
          • Giuseppe Magnani, MD
        • 副研究员:
          • Giordano Cecchetti, MD
        • 副研究员:
          • Francesca Caso, MD
        • 副研究员:
          • Roberto Santangelo, MD
        • 副研究员:
          • Gioele Spinelli, MD
        • 副研究员:
          • Giulia Rugarli, MD
        • 副研究员:
          • Federico Coraglia, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

取样方法

非概率样本

研究人群

Adult patients attending the Cognitive Disorders and Dementia Center (CDCD) at IRCCS San Raffaele Hospital, Milan, Italy, presenting with subjective or objective cognitive complaints of progressive and suspected neurodegenerative nature.

描述

Inclusion Criteria (main study and sub-study):

  1. Age greater than or equal to 40 years (patients of childbearing age are admitted).
  2. Subjective or objective cognitive complaints, progressive in nature and of suspected neurodegenerative origin.
  3. Mini-Mental State Examination (MMSE) score greater than or equal to 18.

    Additional inclusion criterion for the validation sub-study:

  4. Availability of CSF biomarkers for Alzheimer's disease within 6 months of the blood draw.

Exclusion Criteria (main study):

  1. Secondary forms of cognitive impairment based on medical history, neurological examination, and neuroimaging findings.
  2. Pregnancy or breastfeeding.
  3. Rapidly progressive cognitive decline occurring over weeks or months, typically indicative of prion disease, neoplasia, or metabolic disorders.
  4. Subjects who require a legal guardian or tutor.

Exclusion Criteria (validation sub-study):

  1. Secondary forms of cognitive impairment based on medical history, neurological examination, and neuroimaging findings.
  2. Pregnancy.
  3. Rapidly progressive cognitive decline occurring over weeks or months, typically indicative of prion disease, neoplasia, or metabolic disorders.
  4. Subjects who are unable to give informed consent and require a legal guardian or tutor.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
Main Study Cohort
2000 adult patients attending the Cognitive Disorders and Dementia Center (CDCD) at IRCCS San Raffaele Hospital with subjective or objective cognitive complaints of progressive and suspected neurodegenerative nature. All patients undergo annual blood sampling for 5 years in addition to standard clinical follow-up.
A blood sample is collected once per year for 5 years (additional procedure beyond standard clinical care) for measurement of plasma biomarkers including: Abeta40, Abeta42, Abeta42/Abeta40 ratio, pTau-181, NfL, ApoE, ApoE4, GFAP, sTREM2, and other plasma neurodegeneration biomarkers. Blood draw is a routine clinical procedure with no specific contraindications. The only possible side effect is local hematoma at the puncture site. Plasma biomarker measurement is performed using a CE-marked medical device (Fujirebio, provided on free loan). Results do not modify the patient's standard diagnostic and therapeutic pathway.
Validation Sub-study Cohort
150 patients from the main cohort who undergo lumbar puncture as part of their routine diagnostic workup and have CSF biomarkers for Alzheimer's disease available within 6 months of blood draw. Only those with CSF biomarkers confirming a biological diagnosis of Alzheimer's disease continue longitudinal follow-up in the sub-study.
A blood sample is collected once per year for 5 years (additional procedure beyond standard clinical care) for measurement of plasma biomarkers including: Abeta40, Abeta42, Abeta42/Abeta40 ratio, pTau-181, NfL, ApoE, ApoE4, GFAP, sTREM2, and other plasma neurodegeneration biomarkers. Blood draw is a routine clinical procedure with no specific contraindications. The only possible side effect is local hematoma at the puncture site. Plasma biomarker measurement is performed using a CE-marked medical device (Fujirebio, provided on free loan). Results do not modify the patient's standard diagnostic and therapeutic pathway.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Time to progression to all-cause dementia in MCI patients (primary prognostic endpoint)
大体时间:Annually from baseline up to 5 years
Time to clinical progression to all-cause dementia in patients with Mild Cognitive Impairment (MCI) at baseline, assessed using multivariable Cox proportional hazards models. For each plasma biomarker, patients are divided into two groups (above/below the median) and compared using the log-rank test (cause-specific hazard). The study has greater than 95% power to detect a Hazard Ratio of 2 and approximately 75-80% power for HR of 1.5.
Annually from baseline up to 5 years

次要结果测量

结果测量
措施说明
大体时间
Change in MMSE score over time
大体时间:Annually from baseline up to 5 years
Change over time in Mini-Mental State Examination (MMSE) score as a measure of cognitive progression. A decrease of 5 or more points is considered clinically significant progression of cognitive impairment due to AD.
Annually from baseline up to 5 years
Conversion from MCI to Alzheimer's disease dementia
大体时间:Annually from baseline up to 5 years
Rate of clinical conversion from Mild Cognitive Impairment (MCI) to Alzheimer's disease dementia over the 5-year follow-up period, assessed at each annual visit.
Annually from baseline up to 5 years
Longitudinal change in plasma Abeta42/Abeta40 ratio
大体时间:Annually from baseline up to 5 years
Change over time in the plasma Abeta42/Abeta40 ratio, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Annually from baseline up to 5 years
Longitudinal change in plasma pTau-181 levels
大体时间:Annually from baseline up to 5 years
Change over time in plasma phosphorylated tau 181 (pTau-181) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Annually from baseline up to 5 years
Longitudinal change in plasma NfL levels
大体时间:Annually from baseline up to 5 years
Change over time in plasma neurofilament light chain (NfL) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Annually from baseline up to 5 years
Longitudinal change in plasma GFAP levels
大体时间:Annually from baseline up to 5 years
Change over time in plasma Glial Fibrillary Acidic Protein (GFAP) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Annually from baseline up to 5 years
Longitudinal change in plasma sTREM2 levels
大体时间:Annually from baseline up to 5 years
Change over time in plasma soluble Triggering Receptor Expressed on Myeloid cells 2 (sTREM2) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Annually from baseline up to 5 years
Longitudinal change in plasma Abeta40 levels
大体时间:Annually from baseline up to 5 years
Change over time in plasma beta-amyloid 40 (Abeta40) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Annually from baseline up to 5 years
Longitudinal change in plasma Abeta42 levels
大体时间:Annually from baseline up to 5 years
Change over time in plasma beta-amyloid 42 (Abeta42) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Annually from baseline up to 5 years

其他结果措施

结果测量
措施说明
大体时间
Diagnostic accuracy of plasma Abeta42/Abeta40 ratio vs CSF gold standard (sub-study)
大体时间:Baseline (at time of lumbar puncture, within 6 months of blood draw)
Area under the ROC curve (AUC), sensitivity, and specificity of plasma Abeta42/Abeta40 ratio in diagnosing Alzheimer's disease, using CSF biomarkers (CSF-Abeta40, CSF-Abeta42, CSF-pTau, CSF-NfL) as the gold standard. Patients are classified as AD or non-AD based on CSF results. An AUC of at least 0.80 is expected, with greater than 95% power to reject H0: AUC=0.50 at alpha=0.05.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Diagnostic accuracy of plasma pTau-181 vs CSF gold standard (sub-study)
大体时间:Baseline (at time of lumbar puncture, within 6 months of blood draw)
Area under the ROC curve (AUC), sensitivity, and specificity of plasma pTau-181 in diagnosing Alzheimer's disease, using CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Diagnostic accuracy of plasma NfL vs CSF gold standard (sub-study)
大体时间:Baseline (at time of lumbar puncture, within 6 months of blood draw)
Area under the ROC curve (AUC), sensitivity, and specificity of plasma NfL in diagnosing Alzheimer's disease, using CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Diagnostic accuracy of plasma GFAP vs CSF gold standard (sub-study)
大体时间:Baseline (at time of lumbar puncture, within 6 months of blood draw)
Area under the ROC curve (AUC), sensitivity, and specificity of plasma GFAP in diagnosing Alzheimer's disease, using CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma Abeta40 vs CSF gold standard (sub-study)
大体时间:Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for Abeta40 biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma Abeta42 vs CSF gold standard (sub-study)
大体时间:Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for Abeta42 biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma Abeta42/Abeta40 ratio vs CSF gold standard (sub-study)
大体时间:Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for Abeta42/Abeta40 ratio biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma pTau-181 vs CSF gold standard (sub-study)
大体时间:Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for pTau-181 biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma NfL vs CSF gold standard (sub-study)
大体时间:Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for NfL biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma GFAP vs CSF gold standard (sub-study)
大体时间:Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for GFAP biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma sTREM2 vs CSF gold standard (sub-study)
大体时间:Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for sTREM2 biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma ApoE vs CSF gold standard (sub-study)
大体时间:Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for ApoE biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma ApoE4 vs CSF gold standard (sub-study)
大体时间:Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for ApoE4 biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Massimo Filippi, Prof, MD、IRCCS San Raffaele

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年9月12日

初级完成 (估计的)

2032年6月1日

研究完成 (估计的)

2032年6月1日

研究注册日期

首次提交

2026年7月16日

首先提交符合 QC 标准的

2026年7月16日

首次发布 (实际的)

2026年7月21日

研究记录更新

最后更新发布 (实际的)

2026年7月21日

上次提交的符合 QC 标准的更新

2026年7月16日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

其他研究编号

  • BLAD

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.